SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-004300
Filing Date
2022-02-28
Accepted
2022-02-28 17:27:05
Documents
13
Period of Report
2022-02-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20220228.htm   iXBRL 8-K 43023
2 EX-1.1 exhibit11-8xk.htm EX-1.1 285866
  Complete submission text file 0001628280-22-004300.txt   519492

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20220228.xsd EX-101.SCH 1932
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20220228_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20220228_pre.xml EX-101.PRE 12528
7 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20220228_htm.xml XML 10900
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 22691681
SIC: 2836 Biological Products, (No Diagnostic Substances)